Advertisement

Journal of Public Health

, Volume 24, Issue 3, pp 193–207 | Cite as

Community pharmacy-based opiate substitution treatment and related health services: a study of 508 patients and 111 pharmacies

  • Amanda Laird
  • Carole Hunter
  • Colette Montgomery SardarEmail author
  • Niamh M. Fitzgerald
  • Richard Lowrie
Original Article

Abstract

Background and aims

Community pharmacies have a central role in the provision of opiate substitution therapy (OST) for drug misusers, offering accessible, additional health services within recovery-oriented systems of care. However, little is known about the patients receiving OST, availability and uptake of related services and associated pharmacy characteristics. We aimed to describe OST in terms of patients, pharmacies and services within the UK’s largest health authority, NHS Greater Glasgow and Clyde, Scotland.

Methods

Patients completed semi-structured questionnaires and pharmacists provided summary statistics relating to OST provision.

Results

Responses from 508 patients receiving OST from 111 participating pharmacies revealed an established patient population, with 89 % (449/507) aged 30 years or above and 80 % (387/484) attending the same pharmacy for 1 year or more. Methadone was the main form of OST (96 % (487/508), with 97 % (491/504) receiving supervision. Within pharmacies, OST consumption was supervised in one of four main areas: consultation room, dispensing hatch, quiet/private area or over the counter. Location of supervision was considered suitably private by 96 % of patients. Positive staff attitudes, privacy and the provision of additional health services were key factors influencing choice of pharmacy. Additional health services were offered to 75 % of patients and included information provision (43 %), signposting to other health care providers (72 %) and a Scottish service offering free advice and medicines for minor ailments (74 %).

Conclusion

Patients and pharmacists have developed working relationships, enabling access to multiple services associated with health gain and harm reduction. Further development of enhanced services in community pharmacies is merited.

Keywords

Methadone OST Community pharmacy 

Notes

Acknowledgments

The authors wish to thank Alex Adam, Janine Glen, Susie Heywood, Graeme Morrison and David Thomson for their assistance with data collation, literature review and manuscript development.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Ethical approval and informed consent were not required for this study as it was an evaluation of a current service provided by NHS Greater Glasgow & Clyde (NHS GG&C). Research and Development (R&D) Management Approval was obtained prior to the initiation of the study. The study was undertaken in accordance with the ethical standards of NHS GG&C R&D and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. Anstice S, Strike CJ, Brands B (2009) Supervised methadone consumption: client issues and stigma. Subst Use Misuse 44:794–808CrossRefPubMedGoogle Scholar
  2. Bloor R (2007) Supervised methadone in Staffordshire & Shropshire. A study of factors associated with key outcome variables. Research briefing 25. NHS National Treatment Agency for Substance Misuse, London. Available at: http://www.nta.nhs.uk/uploads/nta_rb25_supervised_methadone.pdf
  3. Britton RM, Scott J (2006) Community pharmacy services to drug misusers in the south west of England: results of the 2003–2004 postal survey. Int J Pharm Pract 14:35–41CrossRefGoogle Scholar
  4. Chief Scientist Office (CSO) (2014) Community pharmacy services for drug misusers: measuring national service delivery and the development of professional attitudes over two decades. Reference CZH/4/998. Chief Scientist Office, Edinburgh. Available at: http://www.cso.scot.nhs.uk/wp-content/uploads/czh4998.pdf
  5. Deering DEA, Sheridan J, Sellman JD, Adamson SJ, Pooley S, Robertson R, Henderson C (2011) Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav 36:636–642CrossRefPubMedGoogle Scholar
  6. Department of Health (England) (DOH) and the Devolved Administrations (2007) Drug misuse and dependence: UK guidelines on clinical management. Department of Health (England), the Scottish Government, Welsh Assembly and Northern Ireland Executive, London. Available at: http://www.nta.nhs.uk/guidance.aspx
  7. Green TC, Dauria EF, Bratberg J, Davis CS, Walley AJ (2015) Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Red J. doi: 10.1186/s12954-015-0058-x Google Scholar
  8. Holland R, Matheson C, Anthony G, Roberts K, Priyadarshi S, Macrae A, Whitelaw E, Appavoo S, Bond C (2012) A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in patients on opiate maintenance treatment. Drug Alcohol Rev 31:483–491CrossRefPubMedGoogle Scholar
  9. Information Services Division (ISD) (2010) Scottish Government Urban Rural Classification 2009–2010. ISD, Edinburgh. Available at: http://www.gov.scot/Publications/2010/08/2010UR
  10. Information Services Division (ISD) (2014) Estimating the prevalence of national and local problem drug use in Scotland 2012/13. ISD, Edinburgh. Available at: http://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2011-11-29/2011-11-29-DrugPrevalence-Report.pdf?
  11. Information Services Division (ISD) (2015) The National drug-related deaths database (Scotland) Report: Analysis of Deaths occurring in 2013. ISD, Edinburgh. Available at: http://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2015-04-28/2015-04-28-NDRDD-Report.pdf
  12. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson R (2010) Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 340:c3172. doi: 10.1136/bmj.c3172 CrossRefGoogle Scholar
  13. Lawrie T, Matheson C, Bond CM, Roberts K (2003) Pharmacy customers’ views and experiences of using pharmacies which provide needle exchange services in Aberdeen and Glasgow, Scotland. Int J Drug Policy 14:445–447CrossRefGoogle Scholar
  14. Lawrie T, Matheson C, Bond CM, Roberts K (2004) Pharmacy customers’ views and experiences of using pharmacies which provide drug misuse services. Drug Alcohol Rev 23:195–202CrossRefPubMedGoogle Scholar
  15. Luger L, Bathia N, Alcorn R, Power R (2000) Involvement of community pharmacists in the care of drug misusers: pharmacy based supervision of methadone consumption. Int J Drug Policy 11:227–234CrossRefPubMedGoogle Scholar
  16. Maas J, Barton G, Maskrey V, Pinto H, Holland R (2013) Economic evaluation: a comparison of methadone versus buprenorphone for opiate substitution treatment. Drug Alcohol Depend 133:494–501CrossRefPubMedGoogle Scholar
  17. Mackridge AJ, Beynon CM, McVeigh J, Whitfield M, Chandler M (2010) Meeting the health needs of problematic drug users through community pharmacy: a qualitative study. J Subst Use 15:367–376CrossRefGoogle Scholar
  18. Madden A, Lea T, Bath N, Winstock AR (2008) Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev 27:671–678CrossRefPubMedGoogle Scholar
  19. Matheson C, Bond CM, Mollison J (1999) Attitudinal factors associated with community pharmacists’ involvement in services for drug misusers. Addiction 94:1349–1359CrossRefPubMedGoogle Scholar
  20. Matheson C, Bond CM, Tinelli M (2007) Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health 29:350–357CrossRefGoogle Scholar
  21. Mattick RP, Breen C, Kimber J, Davoli M (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev (3): CD002209. doi: 10.1002/14651858.CD002209.pub2 PubMedGoogle Scholar
  22. National Institute for Health and Care Excellence (NICE) (2007) Methadone and buprenorphine for the management of opioid dependence. NICE, London, Available at: http://www.nice.org.uk/guidance/ta114/resources/guidance-methadone-and-buprenorphine-for-the-management-of-opioid-dependence-pdf
  23. Neale J (1998) Drug users’ views of prescribed methadone. Drugs Educ Prev Policy 5:33–45CrossRefGoogle Scholar
  24. NHS Health Scotland (2009) Educational interventions to prevent hepatitis C: a review of the literature and expert opinion. NHS Health Scotland, Edinburgh, Available at: http://www.healthscotland.com/documents/3580.aspx
  25. Notley C, Holland R, Kouimtsidis C, Maskrey V, Robinson A, Swift L, Harvey I, Schifano F, Lowe A, Rosenbloom K (2014) Pharmacist and patient views of supervised consumption—findings from a randomised controlled trial and qualitative study of supervised consumption in patients managed with opiate maintenance treatment. Int J Pharm Pract 22(S1):19Google Scholar
  26. Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, McAllister G, Gunson R, Hutchinson SJ (2014) Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One 9(8):e104515CrossRefPubMedPubMedCentralGoogle Scholar
  27. Roberts K, Hunter C (2004) A comprehensive system of pharmaceutical care for drug misusers. Harm Red J 1:1–6CrossRefGoogle Scholar
  28. Roberts K, McNulty H, Gruer L, Scott R, Bryson S (1997) The role of Glasgow pharmacists in the management of drug misuse. Int J Drug Policy 9:187–194CrossRefGoogle Scholar
  29. Roe B (2010) Developing nursing practice, treatment and support services for ageing drug users. Nurs Times 106:20–21PubMedGoogle Scholar
  30. Roe B, Beynon C, Pickering L, Duffy P (2010) Experiences of drug use and ageing: health, quality of life, relationship and service implications. J Adv Nurs 66:1968–1979CrossRefPubMedPubMedCentralGoogle Scholar
  31. Royal College of General Practitioners (RCGP) (2011) Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care. RCGP, London, Available at: http://www.rcgp.org.uk/clinical-and-research/clinical-resources/substance-misuse-resources-for-gps.aspx
  32. Scotland A (2012) Health inequalities in Scotland. Audit Scotland, Edinburgh, Available at: http://www.audit-scotland.gov.uk/docs/health/2012/nr_121213_health_inequalities.pdf
  33. Scottish Drug Strategy Delivery Commission (SDSDC) (2013) Independent expert review of opioid replacement therapies in Scotland. SDSDC, Edinburgh, Available at: http://www.gov.scot/Resource/0043/00431023.pdf
  34. Scottish Drugs Forum (SDF) (2007) on behalf of the Scottish Association of Alcohol and Drug Action Teams. Drugs and poverty: a literature review. SDF, Glasgow. Available at: http://www.sdf.org.uk/index.php/resources/publications/
  35. Scottish Drugs Forum (SDF) (2009) Older drug users in Scotland: professionals’ views. SDF, Glasgow, Available at: http://www.sdf.org.uk/resources/reports-and-research/#7
  36. Scottish Government (2008) The road to recovery: a new approach to tackling Scotland’s drug problem. The Scottish Government, Edinburgh, Available at: http://www.scotland.gov.uk/Publications/2008/05/22161610/12
  37. Scottish Government (2009) Establishing effective therapeutic partnerships—a generic framework to underpin the chronic medication service element of the community pharmacy contract. The Scottish Government Edinburgh, Edinburgh, Available at: http://www.gov.scot/Publications/2010/01/07144120/16
  38. Scottish Government (2011) The sexual health and blood borne virus framework 2011–15. The Scottish Government, Edinburgh, Available at: http://www.gov.scot/Resource/Doc/356286/0120395.pdf
  39. Scottish Government (2014) Service evaluation of Scotland’s national take-home naloxone programme. The Scottish Government, Edinburgh, Available at: http://www.gov.scot/Resource/0045/00451251.pdf
  40. Scottish Government Social Research (2009) Assessing the scale and impact of illicit drug markets in Scotland. The Scottish Government, Edinburgh, Available at: www.gov.scot/Publications/2009/10/06103906/0
  41. Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J (2003) The role of methadone in drug-related deaths in the West of Scotland. Addiction 98:995–1002CrossRefPubMedGoogle Scholar
  42. Sheridan J, Manning V, Ridge G, Mayet S, Strang J (2007) Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction 102:1824–1830CrossRefPubMedGoogle Scholar
  43. Strang J, Hall W, Hickman M, Bird S (2010) Impact of supervision of methadone consumption on deaths related to methadone overdose (1993–2008): analyses using OD4 index in England and Scotland. BMJ 341:c4851. doi: 10.1136/bmj.c4851 CrossRefPubMedPubMedCentralGoogle Scholar
  44. Winstock A, Lea T, Sheridan JL (2008) Patients’ help-seeking behaviours for health problems associated with methadone and buprenorphine treatment. Drug Alcohol Rev 27:393–397CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Amanda Laird
    • 1
  • Carole Hunter
    • 1
  • Colette Montgomery Sardar
    • 2
    Email author
  • Niamh M. Fitzgerald
    • 3
  • Richard Lowrie
    • 2
  1. 1.NHS Greater Glasgow & Clyde Addiction Services, Possilpark Health and Care CentreGlasgowScotland
  2. 2.NHS Greater Glasgow & Clyde Pharmacy & Prescribing Support Unit, West Glasgow Ambulatory Care HospitalGlasgowScotland
  3. 3.Institute for Social Marketing, UK Centre for Tobacco and Alcohol StudiesUniversity of StirlingStirlingScotland

Personalised recommendations